Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1962 1
1963 1
1964 3
1966 2
1967 2
1968 4
1969 1
1970 4
1972 1
1975 1
1976 3
1978 2
1979 2
1980 5
1981 2
1983 2
1984 8
1985 4
1986 4
1987 4
1988 3
1989 3
1990 1
1991 1
1992 6
1993 2
1994 2
1995 4
1996 6
1997 5
1998 1
1999 3
2001 4
2002 5
2004 2
2005 7
2006 5
2007 4
2008 5
2009 10
2010 13
2011 13
2012 13
2013 11
2014 7
2015 14
2016 9
2017 11
2018 15
2019 22
2020 21
2021 27
2022 25
2023 17
2024 22
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

359 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Kuruvilla J, et al. Among authors: perini gf. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Wang ML, et al. Among authors: perini gf. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35657079 Clinical Trial.
Depression in cancer: The many biobehavioral pathways driving tumor progression.
Bortolato B, Hyphantis TN, Valpione S, Perini G, Maes M, Morris G, Kubera M, Köhler CA, Fernandes BS, Stubbs B, Pavlidis N, Carvalho AF. Bortolato B, et al. Among authors: perini g. Cancer Treat Rev. 2017 Jan;52:58-70. doi: 10.1016/j.ctrv.2016.11.004. Epub 2016 Nov 16. Cancer Treat Rev. 2017. PMID: 27894012 Review.
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P. Zinzani PL, et al. Among authors: perini gf. Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. Blood. 2023. PMID: 37130017 Free PMC article. Clinical Trial.
CHAF1A Blocks Neuronal Differentiation and Promotes Neuroblastoma Oncogenesis via Metabolic Reprogramming.
Tao L, Moreno-Smith M, Ibarra-García-Padilla R, Milazzo G, Drolet NA, Hernandez BE, Oh YS, Patel I, Kim JJ, Zorman B, Patel T, Kamal AHM, Zhao Y, Hicks J, Vasudevan SA, Putluri N, Coarfa C, Sumazin P, Perini G, Parchem RJ, Uribe RA, Barbieri E. Tao L, et al. Among authors: perini g. Adv Sci (Weinh). 2021 Oct;8(19):e2005047. doi: 10.1002/advs.202005047. Epub 2021 Aug 8. Adv Sci (Weinh). 2021. PMID: 34365742 Free PMC article.
Myc proteins in cell biology and pathology.
Majello B, Perini G. Majello B, et al. Among authors: perini g. Biochim Biophys Acta. 2015 May;1849(5):467-8. doi: 10.1016/j.bbagrm.2014.12.006. Epub 2014 Dec 20. Biochim Biophys Acta. 2015. PMID: 25534969 No abstract available.
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.
Murray JE, Valli E, Milazzo G, Mayoh C, Gifford AJ, Fletcher JI, Xue C, Jayatilleke N, Salehzadeh F, Gamble LD, Rouaen JRC, Carter DR, Forgham H, Sekyere EO, Keating J, Eden G, Allan S, Alfred S, Kusuma FK, Clark A, Webber H, Russell AJ, de Weck A, Kile BT, Santulli M, De Rosa P, Fleuren EDG, Gao W, Wilkinson-White L, Low JKK, Mackay JP, Marshall GM, Hilton DJ, Giorgi FM, Koster J, Perini G, Haber M, Norris MD. Murray JE, et al. Among authors: perini g. Nat Commun. 2024 Jul 11;15(1):5585. doi: 10.1038/s41467-024-49871-0. Nat Commun. 2024. PMID: 38992040 Free PMC article.
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Tao L, Mohammad MA, Milazzo G, Moreno-Smith M, Patel TD, Zorman B, Badachhape A, Hernandez BE, Wolf AB, Zeng Z, Foster JH, Aloisi S, Sumazin P, Zu Y, Hicks J, Ghaghada KB, Putluri N, Perini G, Coarfa C, Barbieri E. Tao L, et al. Among authors: perini g. Nat Commun. 2022 Jun 28;13(1):3728. doi: 10.1038/s41467-022-31331-2. Nat Commun. 2022. PMID: 35764645 Free PMC article.
Editorial: Advances in the treatment of Hodgkin lymphoma.
Mei M, Perini G, Ramchandren R. Mei M, et al. Among authors: perini g. Front Oncol. 2023 Feb 28;13:1164081. doi: 10.3389/fonc.2023.1164081. eCollection 2023. Front Oncol. 2023. PMID: 36925934 Free PMC article. No abstract available.
359 results